Nuveen Asset Management LLC Raises Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Nuveen Asset Management LLC raised its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 10.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 495,727 shares of the biopharmaceutical company's stock after purchasing an additional 48,635 shares during the quarter. Nuveen Asset Management LLC owned 1.01% of Theravance Biopharma worth $4,665,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Newtyn Management LLC lifted its position in Theravance Biopharma by 5.7% in the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after purchasing an additional 258,337 shares during the last quarter. Geode Capital Management LLC lifted its position in Theravance Biopharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock valued at $8,121,000 after purchasing an additional 4,823 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in Theravance Biopharma by 9.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock valued at $7,847,000 after purchasing an additional 69,178 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after purchasing an additional 95,304 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Theravance Biopharma by 2.7% in the fourth quarter. Bank of America Corp DE now owns 481,475 shares of the biopharmaceutical company's stock valued at $4,531,000 after purchasing an additional 12,596 shares during the last quarter. Institutional investors own 99.10% of the company's stock.

Wall Street Analysts Forecast Growth

TBPH has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $11.33.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 24,000 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the sale, the senior vice president now directly owns 336,918 shares of the company's stock, valued at $3,706,098. This represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by insiders.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock traded down $0.11 during midday trading on Wednesday, reaching $11.01. 318,294 shares of the company's stock traded hands, compared to its average volume of 276,922. The company has a market cap of $550.51 million, a PE ratio of -10.90 and a beta of -0.10. The stock has a 50 day moving average of $9.27 and a 200-day moving average of $9.38. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The business had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. On average, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.